258 related articles for article (PubMed ID: 25708258)
21. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease.
Adler J; Sandberg KC; Shpeen BH; Eder SJ; Dhanani M; Clark SJ; Freed GL
J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):35-8. PubMed ID: 23459317
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
[TBL] [Abstract][Full Text] [Related]
23. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
24. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
Lee LY; Sanderson JD; Irving PM
Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
[TBL] [Abstract][Full Text] [Related]
25. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.
Gold SL; Cohen-Mekelburg S; Schneider Y; Shen N; Faggen A; Rupert A; Scherl EJ; Bosworth B; Steinlauf A
Inflamm Bowel Dis; 2017 Oct; 23(10):1882-1889. PubMed ID: 28837521
[TBL] [Abstract][Full Text] [Related]
26. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
27. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
28. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
[TBL] [Abstract][Full Text] [Related]
29. Infliximab in inflammatory bowel disease. Is premedication necessary?
Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
[TBL] [Abstract][Full Text] [Related]
30. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
Lahdenne P; Wikström AM; Aalto K; Kolho KL
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
[TBL] [Abstract][Full Text] [Related]
31. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis: rapid infliximab infusions are safe.
Neef HC; Riebschleger MP; Adler J
Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
[TBL] [Abstract][Full Text] [Related]
33. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
34. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
35. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
36. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
Baert F; Drobne D; Gils A; Vande Casteele N; Hauenstein S; Singh S; Lockton S; Rutgeerts P; Vermeire S
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
[TBL] [Abstract][Full Text] [Related]
39. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
Verma AM; Patel A; Subramanian S; Smith PJ
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
[No Abstract] [Full Text] [Related]
40. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]